# MiPLA

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/MiPLA
> Markdown URL: https://mediated.wiki/source/MiPLA.md
> Source: https://en.wikipedia.org/wiki/MiPLA
> Source revision: 1334194438
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Short description|Chemical compound}}
{{Distinguish|MiPT}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 452010274
| drug_name = 
| image = MIPLSD.svg
| image_class = skin-invert-image
| width = 175px
| image2 = MiPLA 3D.png
| image_class2 = bg-transparent
| width2 = 200px

<!-- Clinical data -->
| tradename = 
| routes_of_administration = [Oral](/source/Oral_administration)<ref name="HalberstadtKleinChatha2019" /><ref name="Shulgin2016" /><ref name="Aipsin" />
| class = [Serotonin receptor modulator](/source/Serotonin_receptor_modulator); [5-HT<sub>2A</sub> receptor agonist](/source/Serotonin_5-HT2A_receptor_agonist); [Serotonergic psychedelic](/source/Serotonergic_psychedelic); [Hallucinogen](/source/Hallucinogen)
| ATC_prefix = None
| ATC_suffix = 

<!-- Legal status -->
| legal_AU = 
| legal_CA = 
| legal_DE = NpSG
| legal_UK = PSA
| legal_US = [Schedule I (isomer of LSD)](/source/List_of_Schedule_I_drugs)
| legal_status = Illegal in France<ref name="LegiFrance">{{cite web|date=20 May 2021|title=Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants|url=https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000043523554|website=www.legifrance.gouv.fr|lang=fr}}</ref>

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| onset = 20–40 minutes<ref name="Aipsin" />
| elimination_half-life = 
| duration_of_action = 4–6 hours<ref name="Aipsin" />
| excretion = 

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 100768-08-9
| PubChem = 57507938
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AC6WQQ5Y4B
| ChemSpiderID = 128916995
| synonyms = MiPLA; MIPLA; Lysergic acid methylisopropylamide; ''N''-Methyl-''N''-isopropyllysergamide; LAMIDE; LA-Me/iso

<!-- Chemical data -->
| IUPAC_name = (8β)-''N''-Isopropyl-''N'',6-dimethyl-9,10-didehydroergoline-8-carboxamide
| C=20 | H=25 | N=3 | O=1 
| SMILES = C4N(C)C1Cc2c[nH]c(ccc3)c2c3C1=CC4C(=O)N(C)C(C)C
| StdInChI=1S/C20H25N3O/c1-12(2)23(4)20(24)14-8-16-15-6-5-7-17-19(15)13(10-21-17)9-18(16)22(3)11-14/h5-8,10,12,14,18,21H,9,11H2,1-4H3
| StdInChIKey=ROICYBLUWUMJFF-UHFFFAOYSA-N
}}

'''MiPLA''', also known as '''''N''-methyl-''N''-isopropyllysergamide''' or as '''lysergic acid methylisopropylamide''', is a [psychedelic drug](/source/psychedelic_drug) of the [lysergamide](/source/substituted_lysergamide) family related to [lysergic acid diethylamide](/source/lysergic_acid_diethylamide) (LSD).<ref name="HuangMarona-LewickaPfaff1994" /><ref name="HalberstadtKleinChatha2019" /> It is taken [orally](/source/oral_administration).<ref name="HalberstadtKleinChatha2019" /><ref name="Shulgin2016" /> The drug is a [structural isomer](/source/structural_isomer) of LSD in which the ''N'',''N''-[diethyl group](/source/ethyl_group)s have been replaced with ''N''-[methyl](/source/methyl_group) and ''N''-[isopropyl group](/source/isopropyl_group)s.<ref name="HuangMarona-LewickaPfaff1994" /><ref name="HalberstadtKleinChatha2019" /><ref name="WachełkoNowakTusiewicz2025">{{cite journal | vauthors = Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P | title = A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies | journal = Analyst | volume = 150 | issue = 2 | pages = 290–308 | date = January 2025 | pmid = 39636448 | doi = 10.1039/d4an01361a | url = }}</ref> It is only somewhat less [potent](/source/potency_(pharmacology)) than LSD as a psychedelic.<ref name="HalberstadtKleinChatha2019" /><ref name="Shulgin2016" /> MiPLA has been encountered as a novel [designer drug](/source/designer_drug).<ref name="HalberstadtKleinChatha2019" /><ref name="TanakaKawamuraHakamatsuka2020" /><ref name="BrandtKavanaghWestphal2022" /><ref name="ShodaTsujiKawamura2024" />

==Use and effects==
MiPLA has about 33% to 50% of the [potency](/source/potency_(pharmacology)) of LSD in producing [psychedelic](/source/psychedelic_drug) effects in humans.<ref name="HalberstadtKleinChatha2019" /><ref name="Shulgin2016" /> According to [Alexander Shulgin](/source/Alexander_Shulgin), it produced LSD-like effects at a dose of 180 to 300{{nbsp}}μg [orally](/source/oral_administration), compared to a dose range of 60 to 200{{nbsp}}μg in the case of LSD.<ref name="HalberstadtKleinChatha2019" /><ref name="Shulgin2016">Shulgin AT (2016) Pharmacology notebook 9. Available online: https://www.erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf [Accessed: January 20, 2018]</ref> Elsewhere, the following has been described about the properties and effects of MiPLA:<ref name="Aipsin">{{cite web | title=MIPLA (Метилизопропиллизергамид) | website=АИПСИН | url=https://aipsin.com/newsubstance/843/ | language=ru | access-date=3 November 2025}}</ref>

: "The primary route of administration for MiPLA is orally. Users report that, despite its lower potency, the hallucinogenic effects of MiPLA are very similar to those of LSD. Users typically describe it as "...soft LSD..." However, some reports indicate that the after-effects are harsh and negative. Active doses range from 50 to 300 mcg, depending on the desired effects. Effects occur within 20 to 40 minutes and last for 4 to 6 hours. It is sold recreationally as blotters or powder."<ref name="Aipsin" />

MiPLA and its [homologue](/source/structural_homolog) [EiPLA](/source/EiPLA) are the only known simple ''N'',''N''-dialkyllysergamides that approach the potency of LSD itself.<ref name="HuangMarona-LewickaPfaff1994">{{cite journal |vauthors=Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE |title=Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives |journal=Pharmacology Biochemistry and Behavior |volume=47 |issue=3 |pages=667–673 |date=March 1994 |pmid=8208787 |doi= 10.1016/0091-3057(94)90172-4|s2cid=16490010 }}</ref> All other ''N'',''N''-dialkyl [analogues](/source/structural_analog) tested, including the [dimethyl](/source/DAM-57), [dipropyl](/source/dipropyllysergamide), [methylethyl](/source/LME-54), and so on, are only around one-tenth as potent as LSD.<ref name="Hofmann_1959">{{cite journal | vauthors = Hofmann A | title = Psychotomimetic drugs; chemical and pharmacological aspects | journal = Acta Physiologica et Pharmacologica Neerlandica | volume = 8 | pages = 240–258 | date = June 1959 | pmid = 13852489 | url = https://www.samorini.it/doc1/alt_aut/ek/hofmann-psychotomimetic-drugs.pdf }}</ref> However, some ''N''-monoalkyllysergamides, such as the [''sec''-butyl](/source/lysergic_acid_2-butyl_amide) and [''tert''-butyl](/source/lysergic_acid_tert-butylamide) derivatives, were also found to show activity and potency comparable to LSD.<ref name="US2997470">{{ cite patent | country = US | number = 2997470 | status = patent | title = Lysergic Acid Amides | pubdate = 1956-03-05 | gdate = 1961-08-22 | inventor = Pioch RP }}</ref> In addition, [iPLA](/source/iPLA), the ''N''-monoisopropyl derivative, is only slightly weaker than MiPLA.<ref name="Nichols2001" /><ref name="PfaffHuangMarona-Lewicka1994">{{cite journal | vauthors = Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE | title = Lysergamides revisited | journal = NIDA Research Monograph | volume = 146 | pages = 52–73 | date = 1994 | pmid = 8742794 | url = https://archives.nida.nih.gov/sites/default/files/monograph146.pdf#page=57 | quote = The series of isopropyl amides has recently been completed with the synthesis of the N-isopropyl, in addition to the N-methyl-N-isopropyl, N-ethyl-N-isopropyl, and the N,N-diisopropyl, as shown in figure 12. With the exception of the N,N-diisopropylamide, all compounds completely substitute in the DD paradigm in rats trained to discriminate LSD from saline. In table 6, the receptor-binding data for displacement of [3H]-ketanserin from rat cortical homogenate are shown. [...] TABLE 6. Radioligand binding data for N-methyl-N-isopropyl lysergamides: [3H]-ketanserin displacement (unpublished results) [...] | archive-date = 2023-08-05 | access-date = 2025-10-22 | archive-url = https://web.archive.org/web/20230805004551/https://archives.nida.nih.gov/sites/default/files/monograph146.pdf#page=57 | url-status = dead }}</ref>

==Interactions==
{{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes}}

==Pharmacology==
===Pharmacodynamics===
MiPLA has been found to interact with [serotonin receptor](/source/serotonin_receptor)s, including acting as an [agonist](/source/agonist) of the [serotonin](/source/serotonin) [5-HT<sub>2A</sub> receptor](/source/5-HT2A_receptor).<ref name="Nichols2018">{{cite book | vauthors = Nichols DE | title = Chemistry and Structure-Activity Relationships of Psychedelics | series = Current Topics in Behavioral Neurosciences | volume = 36 | pages = 1–43 | date = 2018 | pmid = 28401524 | doi = 10.1007/7854_2017_475 | isbn = 978-3-662-55878-2 | url = https://bitnest.netfirms.com/external/10.1007/7854_2017_475}}</ref><ref name="Nichols2012">{{cite journal | vauthors = Nichols DE | title = Structure–activity relationships of serotonin 5-HT2A agonists | journal = Wiley Interdisciplinary Reviews: Membrane Transport and Signaling | volume = 1 | issue = 5 | pages = 559–579 | date = 2012 | doi = 10.1002/wmts.42 | issn = 2190-460X | doi-access = free}}</ref><ref name="HuangMarona-LewickaPfaff1994" /><ref name="PfaffHuangMarona-Lewicka1994" /><ref name="HalberstadtKleinChatha2019">{{cite journal | vauthors = Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, Nichols DE, Brandt SD | title = Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) | journal = Psychopharmacology (Berl) | volume = 236 | issue = 2 | pages = 799–808 | date = February 2019 | pmid = 30298278 | pmc = 6848745 | doi = 10.1007/s00213-018-5055-9 | url = }}</ref><ref name="WattsLawlerFox1995" /><ref name="McCorvy2013">{{cite thesis | vauthors = McCorvy JD | title = Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics | date = 16 January 2013 | degree = Ph.D. | publisher = Purdue University | via = Purdue e-Pubs | url = https://docs.lib.purdue.edu/dissertations/AAI3545320/ | archive-url = https://web.archive.org/web/20250515110801/https://docs.lib.purdue.edu/dissertations/AAI3545320/ | archive-date = 15 May 2025 | access-date = 27 May 2025 | url-status = bot: unknown }}</ref><ref name="Parrish2007">{{cite web | vauthors = Parrish JC | title = Toward a molecular understanding of hallucinogen action | date = 30 October 2007 | website = Purdue e-Pubs | url = https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=5ead04596d21b2918cbacd6d21744aab9f51684e}}</ref><ref name="Braden2007">{{cite thesis | vauthors = Braden MR | title = Towards a biophysical understanding of hallucinogen action | date = 2007 | degree = Ph.D. | publisher = Purdue University | id = {{ProQuest | 304838368}}|url=https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=9a30faca37ad48466b87a192ccd542401dc24012}}</ref> It also interacts with the [dopamine](/source/dopamine) [D<sub>1</sub>](/source/D1_receptor) and [D<sub>2</sub> receptor](/source/D2_receptor)s.<ref name="McCorvy2013" /><ref name="WattsLawlerFox1995">{{cite journal | vauthors = Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB | title = LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors | journal = Psychopharmacology (Berl) | volume = 118 | issue = 4 | pages = 401–409 | date = April 1995 | pmid = 7568626 | doi = 10.1007/BF02245940 | url = }}</ref> The drug fully substitutes for [LSD](/source/LSD) in rodent [drug discrimination](/source/drug_discrimination) tests with only slightly lower [potency](/source/potency_(pharmacology)) than LSD.<ref name="PfaffHuangMarona-Lewicka1994" /><ref name="HuangMarona-LewickaPfaff1994" /><ref name="HalberstadtKleinChatha2019" /><ref name="HalberstadtChathaKlein2020" /> In addition, MiPLA produces the [head-twitch response](/source/head-twitch_response), a behavioral proxy of [psychedelic](/source/psychedelic_drug) effects, in rodents, with about one-third the potency of LSD.<ref name="HalberstadtKleinChatha2019" /><ref name="HalberstadtChathaKlein2020">{{cite journal | vauthors = Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD | title = Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species | journal = Neuropharmacology | volume = 167 | issue = | article-number = 107933 | date = May 2020 | pmid = 31917152 | pmc = 9191653 | doi = 10.1016/j.neuropharm.2019.107933 | url = }}</ref> The drug showed roughly the same potency in producing the head-twitch response as [EcPLA](/source/EcPLA).<ref name="HalberstadtKleinChatha2019" />

==Chemistry==
MiPLA, also known as ''N''-methyl-''N''-isopropyllysergamide or as lysergic acid methylisopropylamide, is a [substituted lysergamide](/source/substituted_lysergamide) and a [structural isomer](/source/structural_isomer) of [lysergic acid diethylamide](/source/lysergic_acid_diethylamide) (LSD; ''N'',''N''-diethyllysergamide), with the [alkyl group](/source/alkyl_group)s on the [amide](/source/amide) [nitrogen](/source/nitrogen) having been subjected to a [methylene shuffle](/source/methylene_shuffle).<ref name="WachełkoNowakTusiewicz2025" />

===Synthesis===
The [chemical synthesis](/source/chemical_synthesis) of MiPLA has been described.<ref name="US2997470" /><ref name="ShodaTsujiKawamura2024">{{cite journal | vauthors = Shoda T, Tsuji G, Kawamura M, Kurohara T, Misawa T, Kikura-Hanajiri R, Demizu Y | title = Structural analysis of an lysergic acid diethylamide (LSD) analogue N-methyl-N-isopropyllysergamide (MiPLA): Insights from Rotamers in NMR spectra | journal = Drug Test Anal | volume = 16 | issue = 6 | pages = 588–594 | date = June 2024 | pmid = 37830386 | doi = 10.1002/dta.3586 | url = }}</ref>

===Analogues===
[Analogue](/source/Structural_analog)s of MiPLA include [iPLA](/source/isopropyllysergamide), [EiPLA](/source/ethylisopropyllysergamide), [EPLA](/source/ethylpropyllysergamide), [EcPLA](/source/ethylcyclopropyllysergamide), [DiPLA](/source/diisopropyllysergamide), [LSB](/source/lysergic_acid_2-butyl_amide), and [LSP](/source/lysergic_acid_3-pentylamide), among others.<ref name="Nichols2018" /> The [ester](/source/ester) [derivative](/source/chemical_derivative)s [1P-MiPLA](/source/1P-MiPLA) and [1cP-MiPLA](/source/1cP-MiPLA) are thought to be [prodrug](/source/prodrug)s of MiPLA.<ref name="WachełkoNowakTusiewicz2025" /><ref name="TusiewiczWachełkoZawadzki2024">{{cite journal | vauthors = Tusiewicz K, Wachełko O, Zawadzki M, Szpot P | title = Forensic Aspects of Designer LSD Analogs Identification by GC-MS (EI) and UV Spectroscopy | journal = Molecules | volume = 29 | issue = 23 | date = December 2024 | page = 5717 | pmid = 39683876 | pmc = 11643092 | doi = 10.3390/molecules29235717 | doi-access = free | url = }}</ref><ref name="TanakaKawamuraMizutani2023">{{cite journal | vauthors = Tanaka R, Kawamura M, Mizutani S, Kikura-Hanajiri R | title = Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products | journal = Forensic Toxicol | volume = 41 | issue = 2 | pages = 294–303 | date = July 2023 | pmid = 36809464 | pmc = 10310582 | doi = 10.1007/s11419-023-00661-1 | url = }}</ref>

==History==
MiPLA was originally discovered and described by [Albert Hofmann](/source/Albert_Hofmann) at [Sandoz](/source/Sandoz) during the original [structure–activity](/source/structure%E2%80%93activity_relationship) research into LSD, with [Eli Lilly and Company](/source/Eli_Lilly_and_Company) filing a [patent](/source/patent) in 1956 and it being published in 1961.<ref name="US2997470" /> It was subsequently investigated in more detail by the team led by [David E. Nichols](/source/David_E._Nichols) at [Purdue University](/source/Purdue_University) in the 1990s.<ref name="HalberstadtKleinChatha2019" /><ref name="PfaffHuangMarona-Lewicka1994" /><ref name="HuangMarona-LewickaPfaff1994" /> The main use for this drug has been in studies of the binding site at the [serotonin](/source/serotonin) [5-HT<sub>2A</sub> receptor](/source/5-HT2A_receptor) through which LSD produces its [hallucinogen](/source/hallucinogen)ic effects.<ref name="Nichols2001">{{cite journal | vauthors = Nichols DE | title = LSD and its lysergamide cousins. | journal = The Heffter Review of Psychedelic Research | location = Santa Fe, New Mexico | publisher = Heffter Research Institute | date = 2001 | volume = 2 | pages = 80–87 | url = https://www.thevespiary.org/rhodium/Rhodium/Vespiary/talk/files/5022-chap6c758.pdf }}</ref> MiPLA was first encountered as a novel [designer drug](/source/designer_drug) by 2018.<ref name="HalberstadtKleinChatha2019" /><ref name="TanakaKawamuraHakamatsuka2020">{{cite journal | vauthors = Tanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R | title = シート状危険ドラッグ製品中のLSD誘導体1cP-LSD, MIPLA, 1B-LSDの同定 | trans-title = Identification of LSD Derivatives, 1cP-LSD, MIPLA and 1B-LSD in Illegal Products as Paper Sheet | language = Japanese | journal = Yakugaku Zasshi | volume = 140 | issue = 11 | pages = 1405–1413 | date = 2020 | pmid = 33132277 | doi = 10.1248/yakushi.20-00124 | url = | doi-access = free }}</ref><ref name="BrandtKavanaghWestphal2022">{{cite journal | vauthors = Brandt SD, Kavanagh PV, Westphal F, Stratford A, Blanckaert P, Dowling G, Grill M, Schwelm HM, Auwärter V, Chapman SJ | title = Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA | journal = Drug Test Anal | volume = 14 | issue = 3 | pages = 545–556 | date = March 2022 | pmid = 34022102 | doi = 10.1002/dta.3103 | url = | doi-access = free }}</ref><ref name="ShodaTsujiKawamura2024"/>

==Society and culture==
===Legal status===
====Austria====
MiPLA is technically not illegal in [Austria](/source/Austria) but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.{{Citation needed|date=October 2025}}

====Canada====
MiPLA is not a [controlled substance](/source/controlled_substance) in [Canada](/source/Canada) as of 2025.<ref name="CDSA">{{cite web | title=Controlled Drugs and Substances Act | website=Department of Justice Canada | url=https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html | access-date=19 January 2026}}</ref>

====France====
MiPLA is illegal in [France](/source/France).<ref name="LegiFrance" />

====Germany====
MiPLA is controlled in [Germany](/source/Germany) under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083–1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>

====Switzerland====
MiPLA can be considered a controlled substance in [Switzerland](/source/Switzerland) as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>

====United Kingdom====
MiPLA is a controlled substance in the [United Kingdom](/source/United_Kingdom) via the [Psychoactive Substances Act 2016](/source/Psychoactive_Substances_Act_2016).{{Citation needed|date=October 2025}}

====United States====
MiPLA is not scheduled in the [United States](/source/United_States),<ref name="OrangeBook2026">{{citation | title = Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) | date = January 2026 | publisher = U.S. [Department of Justice](/source/Department_of_Justice): [Drug Enforcement Administration](/source/Drug_Enforcement_Administration) (DEA): Diversion Control Division | location = [United States](/source/United_States) | url = https://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf}}</ref> but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the [Federal Analogue Act](/source/Federal_Analogue_Act).{{Citation needed|date=October 2025}} However, it may be a Schedule I controlled substance in the United States due to being an [isomer](/source/isomer) of LSD.<ref name="WachełkoNowakTusiewicz2025" /><ref name="DEA2007">{{cite web | author=[Drug Enforcement Administration](/source/Drug_Enforcement_Administration) | title=Definition of “Positional Isomer” as It Pertains to the Control of Schedule I Controlled Substances | website=Federal Register | date=3 December 2007 | url=https://www.federalregister.gov/documents/2007/12/03/E7-23413/definition-of-positional-isomer-as-it-pertains-to-the-control-of-schedule-i-controlled-substances}}</ref>

==See also==
* [Substituted lysergamide](/source/Substituted_lysergamide)
* [Lizard Labs](/source/Lizard_Labs)

==References==
{{Reflist}}

==External links==
* [https://isomerdesign.com/pihkal/explore/5327 MiPLA - Isomer Design]
* [https://psychonautwiki.org/wiki/MiPLA MiPLA - PsychonautWiki]
* [https://www.bluelight.org/xf/threads/784440 The Small & Handy MIPLA-(Methylisopropyllysergamide) Thread - Bluelight]
* [https://tripsitter.substack.com/p/designer-drugs-lysergamides#:~:text=MiPLA%20(N%2DMethyl%2DN%2Disopropyllysergamide) MiPLA - Designer Drug Exposé: Lysergamides - TripSitter]

{{Psychedelics}}
{{Serotonin receptor modulators}}
{{Dopamine receptor modulators}}
{{Ergolines}}

Category:5-HT2A agonists
Category:5-HT2C agonists
Category:Carboxamides
Category:David E. Nichols
Category:Designer drugs
Category:Dopamine receptor modulators
Category:Isopropyl compounds
Category:Lizard Labs
Category:Methyl compounds
Category:Psychedelic lysergamides
Category:Serotonin receptor modulators

---
Adapted from the Wikipedia article [MiPLA](https://en.wikipedia.org/wiki/MiPLA) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/MiPLA?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.